| scholarly article | Q13442814 |
| P50 | author | Derek P. Jewell | Q110729320 |
| P2093 | author name string | Travis SP | |
| Jakobovits SL | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ulcerative colitis | Q1477 |
| P304 | page(s) | 1055-1060 | |
| P577 | publication date | 2007-05-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. | |
| P478 | volume | 25 |
| Q37814549 | A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. |
| Q46846798 | A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization |
| Q38204993 | Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis |
| Q33408842 | All that bleeds is not infliximab-refractory ulcerative colitis |
| Q35745374 | C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study |
| Q41660559 | Can We Predict the Efficacy of Anti-TNF-α Agents? |
| Q35026302 | Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update |
| Q53122367 | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. |
| Q36892770 | Clinical pharmacokinetics and use of infliximab |
| Q38056526 | Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article |
| Q51665884 | Derivation of a T2-weighted MRI total colonic inflammation score (TCIS) for assessment of patients with severe acute inflammatory colitis-a preliminary study. |
| Q44593368 | Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis |
| Q40405779 | Does CT influence the decision to perform colectomy in patients with severe ulcerative colitis? |
| Q43024877 | Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus |
| Q89821548 | Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report |
| Q38258954 | European evidence based consensus on surgery for ulcerative colitis |
| Q34025054 | European evidence-based Consensus on the management of ulcerative colitis: Current management |
| Q45160532 | Exploring the ameliorative potential of probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum on dextran sodium sulphate induced colitis in mice |
| Q88541180 | Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis |
| Q42008025 | Hypersensitivity to mesalazine in a patient with inflammatory bowel disease: a case report. |
| Q42487704 | Immunoprotective Effect of Probiotic Dahi Containing Lactobacillus acidophilus and Bifidobacterium bifidum on Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice |
| Q26771136 | Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis |
| Q46875109 | Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. |
| Q51695695 | Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. |
| Q40708429 | Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study). |
| Q46130626 | Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. |
| Q35026410 | Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years |
| Q38056807 | Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis |
| Q44188398 | Letter: infliximab in severe ulcerative colitis - is it useful for all patients? |
| Q53111236 | Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea. |
| Q44979663 | Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis |
| Q53535882 | Oral administration of Lactobacillus paracasei alleviates clinical symptoms of colitis induced by dextran sulphate sodium salt in BALB/c mice. |
| Q38240881 | Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis |
| Q34528270 | Review article: acute severe ulcerative colitis - evidence-based consensus statements. |
| Q37772188 | Review article: the optimal medical management of acute severe ulcerative colitis. |
| Q35883580 | Review article: the practical management of acute severe ulcerative colitis |
| Q37503367 | Selecting appropriate anti-TNF agents in inflammatory bowel disease |
| Q37189011 | Steroid-refractory severe ulcerative colitis: what are the available treatment options? |
| Q64107563 | Surgery in the age of biologics |
| Q38575522 | Surgical and medical treatment in patients with acute severe ulcerative colitis |
| Q42728456 | Surgical treatment of ulcerative colitis in the biologic therapy era. |
| Q39037681 | The biologics of ulcerative colitis |
| Q37814560 | The pattern and outcome of acute severe colitis |
| Q37122235 | Therapeutic effects of four strains of probiotics on experimental colitis in mice |
| Q37345935 | Therapeutic options in acute severe ulcerative colitis |
| Q37318035 | Therapeutic strategies for the management of ulcerative colitis. |
| Q35882026 | Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study |
| Q37256032 | Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis |
Search more.